Target Validation

Target validation ensures that the target is expressed and then confirms if the engagement of the target has any potential therapeutic benefit. It is a critical step in the early phase of drug development. Our scientists at Cellomatics offer target validation assay design and support for a wide range of projects. 

Target validation includes the following stages:
  • Discovering a biomolecule of interest
  • Investigating the expression of the molecular target within the tissue of interest
  • Evaluating its potential as a target to understand if it is directly involved in the disease process
  • Designing a bioassay to measure biological activity to verify if target modulation produces the desired therapeutic effect
  • Constructing a high-throughput screen
  • Performing screening to find hits and evaluating the hits
We offer a range of strategies and capabilities for modulating gene expression in vitro. These include but are not limited to the use of antibodies, negative dominant controls, antisense oligonucleotides, ribozymes, and small-interfering RNAs.
aspirational CRO conducting high-quality scientific research in laboratory
Our services to support target validation and discovery:
  • We can offer support and assay design for protein and novel target expression in a range of normal and diseased tissue, including:
    • IHC and novel marker assay development & co-localisation studies
    • Phosphorylated marker assay development
  • High-throughput target validation assay that represents biology
  • Molecular level
    • Screen enzyme inhibitors or activators
  • Cellular Level
    • Verify the involvement of the protein in the disease state (often use gene silencing siRNAs)
    • Understand the protein pathways and interactions

HeLA cells were transfected with the siGLO™ transfector indicator (A), siNegative Control and siWRN according to the manufacturer’s instructions. WRN gene expression was assessed 72 hours post-transfection by Quantigene ™ assay (C) and Western Blot (B) to confirm the siRNA knockdown.

Western blot chemiluminescence imaging of basal levels of alpha Smooth Muscle Actin (α-SMA) expression over 72 hours in human lung fibroblasts and mouse lung fibroblasts   

                                                    Immunofluorescence staining of Hela cells expressing α-Smooth Muscle Actin

Request a consultation with Cellomatics Biosciences today

Our experienced team of in vitro laboratory scientists will work with you to understand your cell-based assay development needs and provide a bespoke project plan with a professional, flexible service and a fast turnaround time.

To request a consultation where we can discuss your exact requirements, please contact Cellomatics Biosciences.